Tricyclic inhibitors of matrix metalloproteinases
AssigneeWarner-Lambert Company
InventorsDonald Hupe, Linda Lea Johnson, Joseph Armand Picard, Andrew David White, Qi-Zhuang Ye
Life of this patent
Estimating the term…
Abstract
Tricyclic compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A (72 kD gelatinase) and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, cancer metastasis, tumor angionenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes.
Claims12
A compound of Formula ##STR51## wherein ##STR52## is attached at the 1 or 2 position of the A ring;
- wherein X is
- O, or
- N--OR.sup.6 wherein R.sup.6 is
- hydrogen,
- --(CH.sub.2).sub.n -aryl wherein n is zero or an integer of 1 to 5,
- alkyl, or
- --(CH.sub.2).sub.n -cycloalkyl wherein n is as defined above;
- R and R.sup.a are each the same or different and each is
- hydrogen,
- --(CH.sub.2).sub.n -aryl wherein n is as defined above,
- --(CH.sub.2).sub.n -heteroaryl wherein n is as defined above,
- --(CH.sub.2).sub.p --R.sup.7 --(CH.sub.2).sub.q -aryl wherein R.sup.7 is O or S and p or q is each zero or an integer of 1 to 5 and the sum of p+q equals an integer of 5,
- --(CH.sub.2).sub.p --R.sub.7 --(CH.sub.2).sub.q -heteroaryl wherein p, q, and R.sup.7 are as defined above,
- alkyl,
- --(CH.sub.2).sub.n -cycloalkyl wherein n is as defined above, or
- --(CH.sub.2).sub.r --NH.sub.2 wherein r is an integer of 1 to 9;
- a is zero or an integer of 1 to 3;
- and
- R.sup.5 is
- OH, or
- NH--OR.sup.6 wherein R.sup.6 is as defined above;
- with the proviso that when X is O, and R.sup.5 is not NH--OR.sup.6, at least one of R or R.sup.a is not hydrogen;
- and corresponding isomers thereof;
- or a pharmaceutically acceptable salt thereof.
A compound which is 4-dibenzofuran-2-yl-4-hydroxyimino-butyric acid.
Dependencies are inferred from the claim text.